Semax

What is Semax?#

Semax is a synthetic heptapeptide analog of the adrenocorticotropic hormone (ACTH) fragment 4-7, extended at the C-terminus with a Pro-Gly-Pro (PGP) tripeptide motif. Its full amino acid sequence is Met-Glu-His-Phe-Pro-Gly-Pro. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences beginning in the 1980s, Semax represents one of the most extensively studied nootropic peptides to emerge from Russian pharmaceutical research.

Semax occupies a unique position in the peptide landscape. It is approved as a pharmaceutical product in Russia and several Commonwealth of Independent States (CIS) countries, where it is prescribed for ischemic stroke recovery, cognitive impairment, and optic nerve diseases. It is listed on the Russian List of Vital and Essential Drugs. However, it has never been submitted for regulatory approval in Western markets and remains an unapproved research chemical in the United States, European Union, and most other countries.

Origin and Development#

The development of Semax began with the observation that ACTH fragments, particularly the 4-10 sequence (Met-Glu-His-Phe-Arg-Trp-Gly), possess nootropic and neuroprotective properties independent of the hormone's adrenocortical effects. The ACTH(4-7) fragment (Met-Glu-His-Phe) was identified as the minimal sequence retaining cognitive activity. However, this tetrapeptide has an extremely short half-life in vivo due to rapid degradation by aminopeptidases and carboxypeptidases.

The C-terminal extension with Pro-Gly-Pro was a deliberate design choice to address this stability problem. The PGP tripeptide protects the bioactive core from carboxypeptidase degradation and significantly extends the peptide's biological half-life. Additionally, the PGP sequence itself has been shown to possess independent immunomodulatory properties, potentially contributing to Semax's neuroprotective effects.

A critical feature of Semax's design is that it retains the cognitive and neurotrophic properties of ACTH fragments while lacking the adrenocortical activity of the full ACTH molecule. At therapeutic doses, Semax does not stimulate cortisol release, does not affect adrenal function, and does not produce the metabolic side effects associated with corticosteroid administration. This dissociation of nootropic effects from hormonal effects was a primary goal of the drug design program.

Mechanism of Action#

Semax's mechanism of action is multifaceted and involves several converging pathways in the central nervous system.

Neurotrophic Factor Upregulation#

The most well-characterized mechanism is the upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression. Research by Dolotov et al. (2006) demonstrated that a single intranasal dose of Semax (50 mcg/kg) produces a 1.4-fold increase in BDNF protein levels and a 1.6-fold increase in trkB tyrosine phosphorylation in the rat hippocampus. At the mRNA level, exon III BDNF showed a 3-fold increase and trkB mRNA a 2-fold increase (PMID: 16996037).

The neurotrophic effects are region-specific and time-dependent. Shadrina et al. (2010) showed that Semax induces multidirectional activation of NGF and BDNF gene expression across the hippocampus, frontal cortex, and retina, with the pattern varying by brain region and time after administration (PMID: 19662538).

Semax also has specific binding sites in the basal forebrain. Dolotov et al. (2006) characterized this binding as time-dependent, specific, reversible, and calcium-dependent, with a dissociation constant (KD) of 2.4 nM. The binding was associated with increased BDNF protein levels at doses of 50 and 250 mcg/kg (PMID: 16635254).

Dopaminergic and Serotoninergic Modulation#

Eremin et al. (2005) demonstrated that Semax activates both dopaminergic and serotoninergic brain systems in rodents. The peptide produced significant increases in serotonin metabolite levels in the striatum, with extracellular concentrations rising to 180% within 1-4 hours after administration. While Semax alone did not alter baseline dopamine levels, it dramatically potentiated dopamine release when combined with D-amphetamine (PMID: 16362768).

This neurotransmitter modulation provides a neurochemical basis for Semax's reported nootropic effects, as both dopamine and serotonin systems are critically involved in attention, memory consolidation, and cognitive flexibility.

Neuroprotective and Anti-Inflammatory Effects#

In the context of cerebral ischemia, Semax demonstrates neuroprotective effects through gene expression modulation. Medvedeva et al. (2014) performed genome-wide transcriptional analysis showing that Semax affects the expression of 96 genes at 3 hours and 68 genes at 24 hours post-stroke. The immune response was identified as the process most markedly affected, with immunoglobulin genes showing up to 15-fold increases in expression and chemokine genes substantially upregulated (PMID: 24661604).

In ischemic brain tissue, Semax selectively upregulates neurotrophin transcription: BDNF, TrkC, and TrkA at 3 hours; NT-3 and NGF at 24 hours; and NGF again at 72 hours post-occlusion. This sustained neurotrophic response contributes to the survival of ischemic cells (PMID: 19633950).

Clinical Applications in Russia#

Ischemic Stroke#

Semax's primary approved indication in Russia is the treatment of acute ischemic stroke and stroke recovery. Clinical investigations by Myasoedova et al. (1999) demonstrated that Semax at doses of 100-150 mcg/kg displays angioprotective, antihypoxic, and neurotrophic activity. The drug shifts neuromediatory balance toward anti-inflammatory agents (IL-10, TNF-alpha modulation) while reducing pro-inflammatory markers (IL-8, CRP) during acute ischemic stroke recovery (PMID: 10358912).

In Russian clinical practice, Semax is administered intranasally at a 1% concentration (3 mg per dose) for acute stroke, typically initiated within hours of symptom onset and continued for 5-14 days.

Cognitive Disorders and Nootropic Use#

Semax is also prescribed in Russia for cognitive impairment, including age-related cognitive decline, post-traumatic cognitive deficits, and attention disorders. The standard nootropic formulation is a 0.1% intranasal solution (30 mcg per drop), used in treatment courses of 10-14 days.

Tsai (2007) proposed Semax as a potential treatment for attention-deficit hyperactivity disorder (ADHD) and Rett syndrome based on its ability to stimulate memory and attention in rodents and humans, amplify psychostimulant effects on dopamine, and promote BDNF synthesis. Both ADHD and Rett syndrome involve dysfunction in pathways that Semax modulates (PMID: 16996699).

Optic Nerve Disease#

In Russian practice, Semax is used for optic nerve atrophy and other optic nerve diseases. The retina and optic nerve express neurotrophic factor receptors, and Semax's ability to upregulate BDNF and NGF in retinal tissue provides a mechanistic rationale for this application.

Formulations#

Semax is commercially available in Russia in two primary formulations:

Both formulations are administered as intranasal drops, taking advantage of the nasal mucosa's direct access to the central nervous system via the olfactory and trigeminal nerve pathways. This bypasses the blood-brain barrier and first-pass hepatic metabolism.

How Semax Differs from Other ACTH-Derived Peptides#

Semax is distinct from other ACTH fragments and analogs in several important ways:

• Versus full ACTH: Semax lacks adrenocortical activity and does not stimulate cortisol production
• Versus ACTH(4-10): The PGP extension dramatically improves metabolic stability
• Versus Selank: Selank is a tuftsin analog with anxiolytic properties; Semax is an ACTH analog with nootropic properties. They act through different receptor systems
• Versus Cerebrolysin: Cerebrolysin is a mixture of peptide fragments from porcine brain; Semax is a single defined peptide with known sequence

Evidence Assessment#

The evidence base for Semax includes decades of Russian clinical use, numerous preclinical studies published in peer-reviewed journals, and a handful of clinical investigations. However, the evidence has significant limitations from a Western regulatory perspective:

• Most clinical studies were conducted in Russia with limited publication in English-language journals
• No Phase 3 randomized controlled trials meeting Western regulatory standards have been conducted
• The available clinical data often lacks the methodological rigor expected by the FDA or EMA
• Post-marketing surveillance data from Russian use has not been compiled in Western-accessible formats

Despite these limitations, the preclinical evidence for Semax's neurotrophic and neuroprotective mechanisms is robust and has been published in well-regarded international journals.

Evidence Gaps#

• No FDA or EMA clinical trials have been conducted
• Head-to-head comparison with established nootropics not available
• Long-term safety data from controlled studies absent
• Optimal dosing for different indications not established by Western standards
• Mechanism of specific binding and receptor identification incomplete
• Effects on human neurotrophic factor levels not confirmed in controlled studies
• Whether benefits from Russian clinical use translate to Western clinical endpoints is unknown

Key Research Findings#

Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents, published in Neurochemical Research (Eremin KO et al., 2005; PMID: 16362768):

• The study showed serotonin metabolite increase to 180% in striatum within 1-4 hours

Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain, published in Journal of Neurochemistry (Dolotov OV et al., 2006; PMID: 16635254):

• The study showed specific Semax binding with KD of 2.4 nM

The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis, published in BMC Genomics (Medvedeva EV et al., 2014; PMID: 24661604):

• The study showed immunoglobulin genes up to 15-fold upregulated

Comparison of the temporary dynamics of NGF and BDNF gene expression in rat hippocampus, frontal cortex, and retina under Semax action, published in Journal of Molecular Neuroscience (Shadrina M et al., 2010; PMID: 19662538):

• The study showed BDNF elevation in retina by 90 minutes

Related Reading#

• Semax research studies and evidence
• Semax dosing protocols
• Semax side effects profile
• ARA-290 research guide
• Cerebrolysin research guide